Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXEJZO)

Drug Name
LX1001 Drug Info
Synonyms AAVrh.10hAPOE2
Indication
Disease Entry ICD 11 Status REF
Alzheimer disease 8A20 Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMXEJZO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Apolipoprotein E (APOE)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AEM-28 DMI5TXZ Familial hypercholesterolemia 5C80.00 Phase 2 [3]
CN-105 DM0MTP8 Nontraumatic intracerebral hemorrhage 8B00.4 Phase 2 [4]
Apolipoprotein E DMIYTPE Glaucoma/ocular hypertension 9C61 Terminated [5]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apolipoprotein E (APOE) TTKS9CB APOE_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT03634007) A 52-Week, Multicenter, Phase 1/2 Open-label Study to Evaluate the Safety of LX1001 in Participants With APOE4 Homozygote Alzheimer's Disease. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Lexeo Therapeutics
3 Clinical pipeline report, company report or official report of LipimetiX.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem. 1994 Mar;54(3):299-308.